IMVT

31.7402.40%
FM

Frank M. Torti

President & Vant Chair

Dr. Frank M. Torti, M.D., M.B.A. serves as the Chairperson of the Board at Aruvant Sciences, Inc. Dr. Torti serves as Vant Chairman and President at Roivant Sciences Ltd. since July 2025. He served as a Chairperson of the Board at Immunovant, Inc. since December 2019 until August 2, 2021 and is its Executive Chairman of the Board on August 02, 2021. Dr. Torti has served as Chairperson of Immunovant Sciences Ltd‘s board of directors since June 2019 and as its Executive Chairperson since August 2021. He previously served as the investment Chair, where he oversaw a group of companies responsible for the development of 35 investigational drugs in 11 therapeutic areas and over 50 clinical trials, including four successful Phase 3 trials. Dr. Torti serves as Vant Chairman at Roivant Sciences, Inc since 2020. Dr. Torti serves as Chairman of the Board of the companies in the Roivant Pharma and is responsible for the management of those businesses. He served as an Independent Chairman of Board of Directors at Arbutus Biopharma Corporation since November 26, 2018 until February 25, 2025. Dr. Torti joined the Arbutus Biopharma Corporation on November 26, 2018. Dr. Torti has served as the Vant Chair of Roivant Sciences, Inc., or RSI, which is a wholly owned subsidiary of affiliate, RSL, since January 2020. He served as Vant Investment Chair of RSI, from August 2018 to December 2019. Dr. Torti had been a Director of Myovant Sciences Ltd. since November 7, 2018 until December 27, 2019. He serves as Chairman of the Board at Dermavant Sciences Ltd. since August 2018. He served as Member of the Board of Directors at Urovant Sciences Ltd since August 2018 until December 27, 2019. Dr. Torti joined Roivant in 2018 from New Enterprise Associates (NEA), Dr. Torti has been a Vant Investment Chair of Roivant Sciences GmbH since September 3, 2018. Dr. Torti joined Roivant in 2018. Dr. Torti has served as Vant Investment Chair of Roivant Pharma since August 2018. He served as Managing Director and Partner at New Enterprise Associates since August 2007 until August 2018. Dr. Torti joined New Enterprise Associates in 2007 and had previously served as a Principal. From November 2022 to December 2023, Dr. Torti served as Chief Executive Officer of Telavant. He focused on both private and public investments in healthcare, biopharmaceuticals, medical devices and healthcare services. At NEA, Dr. Torti managed early and growth-stage investments in numerous healthcare companies that were responsible for the development and commercialization of new drugs and medical devices important to clinical medicine today. Prior to joining it, Dr. Torti was a Researcher at Duke University Center for Clinical and Genetic Economics from 2002 to 2005 in various capacities, where he was involved in economic evaluations of multinational clinical trials research. Dr. Torti served as Director of Galera Therapeutics, Inc. since February 9, 2013. He had been Director of Tarveda Therapeutics, Inc. (formerly known as Blend Therapeutics, Inc.) since January 27, 2016. He served on the Board of Annexon Biosciences, Inc. He served as Director of OrphoMed, Inc. since May 24, 2017. Dr. Torti serves as Director Tarveda Therapeutics and Genevant Sciences Ltd. He had been a Director of NeoTract, Inc. since July 2014. He served as a Director of Cerecor, Inc. since July 11, 2014 until June 26, 2015. He had been Chairperson of the Board at Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies Ltd.). (formerly known as Axovant Sciences Ltd.) since September 26, 2018 until April 2023. Dr. Torti is also Chairperson of the Board of Directors of Dermavant Sciences Ltd. Dr. Torti has also previously served on the boards of Directors of several development and commercial stage private healthcare companies, including Eargo Inc., Novast Pharmaceuticals Ltd. and XOC Pharmaceuticals, Inc. He received an M.D. from the University of North Carolina, School of Medicine and an M.B.A. with distinction from Harvard Business School and a B.A. with highest honors from the University of North Carolina, where he was a MoreHead Scholar.

Positions